Esperion Therapeutics/$ESPR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Esperion Therapeutics

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Ticker

$ESPR

Sector

Health
Primary listing

Employees

304

ESPR Metrics

BasicAdvanced
$362M
-
-$0.49
0.82
-

What the Analysts think about ESPR

Analyst ratings (Buy, Hold, Sell) for Esperion Therapeutics stock.

Bulls say / Bears say

Settlement agreements with Micro Labs USA and Accord Healthcare delay generic competition for NEXLETOL® in the U.S. until at least April 19, 2040, preserving market exclusivity.
U.S. net product revenue grew 41% year-over-year to $34.9 million in Q1 2025, and Esperion surpassed one million retail prescription equivalents, demonstrating robust commercial traction.
Global expansion through a license and distribution agreement with CSL Seqirus for Australia/New Zealand and an expected Japanese approval by partner Otsuka in H2 2025 diversifies revenue streams and validates international potential.
Total revenue for Q1 2025 declined 53% year-over-year to $65.0 million, reflecting volatility tied to one-time milestone payments and underscoring current revenue concentration.
Esperion posted a $40.5 million net loss in Q1 2025, with a quarterly cash burn of approximately $30 million, leaving roughly four quarters of operational runway at existing cash levels and raising financing risk.
Analysts anticipate sustained losses, with Q2 2025 EPS projected at a $0.15 loss per share and revenue expected to drop about 60.5% year-over-year, indicating persistent top-line pressure.
Data summarised monthly by Lightyear AI. Last updated on 21 Jul 2025.

ESPR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ESPR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ESPR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs